Bayzed Health (HKG:2609) booked a loss attributable to equity shareholders of 13 million yuan for 2025, narrowing from a loss of 13.5 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the oncology-focused healthcare services provider were up over 15% in Wednesday afternoon trade.
Loss per share was 0.01 yuan, unchanged from the prior year.
Revenue declined 5.8% to 1.12 billion yuan from 1.19 billion yuan in 2024.